https://www.selleckchem.com/products/n6f11.html
The 6-month survival rate and PFS were 0.67 (95%CI 0.59-0.74) and 0.36 (95%CI 0.24-0.49), respectively. According to the tumor type (melanoma, NSCLC, and RCC), subgroup analyses indicated that melanoma presented the lowest survival rates among the three groups here selected. In regard to the type of ICIs, the anti-CTLA-4 combined with the anti-PD-1/PD-L1 showed the best survival outcome among these groups. The 12-month survival rate and PFS showed a consistent pattern of findings. In the long-term, the 24-month survival rate and PFS were
Like
Comment
Share
